Pharma Mar S.A./€PHM
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Pharma Mar S.A.
Pharma Mar S.A. is a biopharmaceutical company based in Madrid, Spain, specializing in the research, development, and commercialization of marine-derived drugs. The company's core focus is on oncology, where it develops and produces antitumor drugs. Its product portfolio includes compounds such as Yondelis, Aplidin, and Zepzelca, each targeting various forms of cancer. Founded in 1986, Pharma Mar is part of the pharmaceutical group Zeltia. The company leverages its unique access to marine biodiversity to create differentiated products, positioning itself distinctively within the pharmaceutical industry. Pharma Mar operates globally, with a significant foothold in both European and international markets.
Ticker
€PHM
Sector
Primary listing
BME
Employees
505
Headquarters
Website
Pharma Mar S.A. Metrics
BasicAdvanced
€1.4bn
-
-
-
€1.00
1.26%
Price and volume
Market cap
€1.4bn
52-week high
€106.00
52-week low
€65.00
Average daily volume
56k
Dividend rate
€1.00
Financial strength
Current ratio
2.855
Quick ratio
2.204
Long term debt to equity
13.387
Total debt to equity
18.279
Interest coverage (TTM)
15.81%
Profitability
EBITDA (TTM)
44.827
Gross margin (TTM)
93.38%
Net profit margin (TTM)
25.67%
Operating margin (TTM)
17.78%
Effective tax rate (TTM)
-37.54%
Revenue per employee (TTM)
€430,000
Management effectiveness
Return on assets (TTM)
6.55%
Return on equity (TTM)
24.82%
Valuation
Dividend yield (TTM)
1.26%
Growth
Revenue change (TTM)
15.52%
3-year revenue growth (CAGR)
7.68%
10-year revenue growth (CAGR)
1.50%
3-year dividend per share growth (CAGR)
15.44%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.